About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tnfrsf1btm1Imx
targeted mutation 1, Immunex Research and Development Corporation
MGI:1860087
Summary 6 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx B6.129S7-Tnfrsf1btm1Imx MGI:4830692
hm2
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx involves: 129S7/SvEvBrd * C57BL/6 MGI:2175020
cx3
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
B6.129S-Tnfrsf1btm1Imx Tnfrsf1atm1Imx/J MGI:6433775
cx4
Birc2tm1.1Rbr/Birc2tm1.1Rbr
Birc3tm1.1Rbr/Birc3tm1.1Rbr
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
involves: 129S7/SvEvBrd * BALB/cJ * C57BL/6 * SJL MGI:5319379
cx5
Lepob/Lepob
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
involves: 129S7/SvEvBrd * C57BL/6 MGI:2176437
cx6
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
involves: 129S7/SvEvBrd * C57BL/6 MGI:3689914


Genotype
MGI:4830692
hm1
Allelic
Composition
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
Genetic
Background
B6.129S7-Tnfrsf1btm1Imx
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tnfrsf1btm1Imx mutation (5 available); any Tnfrsf1b mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
skeleton
N
• no increase in bone mineral density

respiratory system
N
• display a rapid increase in peak inspiratory pressure when exposed to high stretch ventilation, as is seen in controls

homeostasis/metabolism
• decreased arterial pO2 after 2 hours of high stretch ventilation
• increased arterial pCO2 after 2 hours of high stretch ventilation

cardiovascular system
• drops below 45mm Hg by 70 minutes of high stretch ventilation whereas controls require 90 minutes




Genotype
MGI:2175020
hm2
Allelic
Composition
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
Genetic
Background
involves: 129S7/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tnfrsf1btm1Imx mutation (5 available); any Tnfrsf1b mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• numbers of microglial cells significantly increased relative to controls after epileptic stimulation
• two hours post i.v. lipopolysaccharide (LPS) challenge serum levels are 5 fold higher than controls, however, TNF kinetics and activity are not altered
• increased pulmonary neutrophil accumulation in response to intranasal instillation of M. faeni as compared to control, however monocyte and lymphocyte levels are comparable to control
• increased numbers of T-gamma,delta cells in broncho-alveolar lavage fluid

homeostasis/metabolism
N
• normal recovery after superficial injury causes an increased trans-epidermal water loss
• 41% loss of striatal dopaminergic neurons in MPTP model of Parkinson's disease (controls lose 70%)
• two hours post i.v. lipopolysaccharide (LPS) challenge serum levels are 5 fold higher than controls, however, TNF kinetics and activity are not altered

nervous system
• 41% loss of striatal dopaminergic neurons in MPTP model of Parkinson's disease (controls lose 70%)
• numbers of microglial cells significantly increased relative to controls after epileptic stimulation
• increased glutamate currents

neoplasm
• development after DMPA/TPA treatment is reduced

respiratory system
• increased numbers of T-gamma,delta cells in broncho-alveolar lavage fluid

hematopoietic system
• numbers of microglial cells significantly increased relative to controls after epileptic stimulation

integument
• development after DMPA/TPA treatment is reduced

cellular
• 41% loss of striatal dopaminergic neurons in MPTP model of Parkinson's disease (controls lose 70%)




Genotype
MGI:6433775
cx3
Allelic
Composition
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
Genetic
Background
B6.129S-Tnfrsf1btm1Imx Tnfrsf1atm1Imx/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tnfrsf1atm1Imx mutation (6 available); any Tnfrsf1a mutation (52 available)
Tnfrsf1btm1Imx mutation (5 available); any Tnfrsf1b mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• mice infected with mouse-adapted SARS-CoV MA15 exhibit protection from weight loss that is seen in wild-type mice and decreased viral titers




Genotype
MGI:5319379
cx4
Allelic
Composition
Birc2tm1.1Rbr/Birc2tm1.1Rbr
Birc3tm1.1Rbr/Birc3tm1.1Rbr
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
Genetic
Background
involves: 129S7/SvEvBrd * BALB/cJ * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Birc2tm1.1Rbr mutation (0 available); any Birc2 mutation (33 available)
Birc3tm1.1Rbr mutation (0 available); any Birc3 mutation (32 available)
Tnfrsf1btm1Imx mutation (5 available); any Tnfrsf1b mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging




Genotype
MGI:2176437
cx5
Allelic
Composition
Lepob/Lepob
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
Genetic
Background
involves: 129S7/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lepob mutation (5 available); any Lep mutation (21 available)
Tnfrsf1atm1Imx mutation (6 available); any Tnfrsf1a mutation (52 available)
Tnfrsf1btm1Imx mutation (5 available); any Tnfrsf1b mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• plasma insulin levels are reduced significantly compared to homozygous Lep mutants
• 52% reduction in plasminogen activator inhibitor (PAI-1) antigen in the plasma
• 78% reduction in PAI-1 mRNA expression and 80% reduction in TGF-beta gene expression in adipose tissue

adipose tissue
• 78% reduction in PAI-1 mRNA expression and 80% reduction in TGF-beta gene expression in adipose tissue




Genotype
MGI:3689914
cx6
Allelic
Composition
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
Genetic
Background
involves: 129S7/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tnfrsf1atm1Imx mutation (6 available); any Tnfrsf1a mutation (52 available)
Tnfrsf1btm1Imx mutation (5 available); any Tnfrsf1b mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• enhanced survival after caecal ligation and puncture

immune system
• reduced microglial response to excitotoxic injury
• two hours post lipopolysaccharide (LPS) challenge serum levels are 15-20 fold higher than controls, however, TNF kinetics and activity are not altered
• following reverse passive Arthus reaction to induce uveitis, mice exhibit reduced cellular infiltration into the anterior and posterior segments compared with wild-type mice
• do not respond to collagen type II injections as do controls by developing arthritis for at least 14 days
• M. faeni- induced neutrophil accumulation in the lung is decreased as compared to control, however monocyte and lymphocyte levels are comparable to control
• exhibits resistance to a lethal LPS dose plus hepatoxin D-gal (increases sensitivity to LPS)
• osteolytic lesions of molars are significantly larger in these mice 2 weeks after bacterial inoculation of the dental pulp
• the osteolytic lesions continue to be larger for at least 38 days after innoculation
• mice have 3 log greater bacterial penetration of the dental pulp eight days after experimental bacterial infection

homeostasis/metabolism
• 40% larger infarction than controls after coronary artery occlusion
• extent of necrosis in ventricles is similar to controls
• apoptosis peaks earlier and higher than for controls
• increased susceptibility to kainic acid damage
• 30-50% neuron loss at kainic acid doses causing only minimal hippocampal damage in controls
• susceptibility to kainic acid damage is not reduced by TNF treatment
• two hours post lipopolysaccharide (LPS) challenge serum levels are 15-20 fold higher than controls, however, TNF kinetics and activity are not altered
• TNF alpha induced thrombus formation is delayed
• hypothermic response to caecal ligation and puncture much shorter in duration than for controls
• febrile response to caecal ligation and puncture earlier in onset in males
• fail to develop fibroproliferative lesions at bronchiolar-alveolar duct junctions when exposed to chrysotile asbestos fibers
• protected against loss of striatal dopaminergic neurons in MPTP model of Parkinson's disease (controls lose 70%)
• also protected against tyrosin hydroxylase loss
• no loss of tyrosine hydroxylase immunoreactive nerve terminals
• significantly increased area of infarct after middle cerebral artery occlusion
• enlarged calluses formed on long bone fractures during healing at days 14, 21, and 28
• bones are fragile and prone to re-breaking
• delayed removal of calcified cartillage
• delayed mesenchymal cell differentiation

cellular
• protected against loss of striatal dopaminergic neurons in MPTP model of Parkinson's disease (controls lose 70%)
• also protected against tyrosin hydroxylase loss
• no loss of tyrosine hydroxylase immunoreactive nerve terminals
• increased susceptibility to kainic acid damage
• 30-50% neuron loss at kainic acid doses causing only minimal hippocampal damage in controls
• susceptibility to kainic acid damage is not reduced by TNF treatment

skeleton
• mice have significantly higher necrosis scores of the dental pulp seven days after bacterial inoculation
• complete necrosis of the dental pulp is observed by 21 days after inoculation compared to control mice that still have intact dental pulp at 38 days post-innoculation
• enlarged calluses formed on long bone fractures during healing at days 14, 21, and 28
• bones are fragile and prone to re-breaking
• delayed removal of calcified cartillage
• delayed mesenchymal cell differentiation
• do not respond to collagen type II injections as do controls by developing arthritis for at least 14 days
• osteolytic lesions of molars are significantly larger in these mice 2 weeks after bacterial inoculation of the dental pulp
• the osteolytic lesions continue to be larger for at least 38 days after innoculation
• no induction of intramembranous bone on periosteal surfaces after 21 days of healing
• lack of trabecular bridging
• delayed formation of new trabecular bone after bone marrow cannulation
• extensive necrotic tissue and hematomas remain 3 days after bone marrow cannulation
• there is significantly more osteoclastogenesis that occurs in molars between 7 and 21 days after bacterial infection of the dental pulp
• osteoclast activity of the molars is almost 2-fold higher than in wild-types 7 days after bacterial inoculation

nervous system
N
• no overt phenotype when unstressed
• 44% higher level of generalized convulsions in the 2 hours following 1 hour of electrical stimulation in the hippocampus
• significantly increased area of infarct after middle cerebral artery occlusion
• glial response to neuronal injury is blunted
• reduced microglial response to excitotoxic injury
• long term neuron survival in culture is reduced
• protected against loss of striatal dopaminergic neurons in MPTP model of Parkinson's disease (controls lose 70%)
• also protected against tyrosin hydroxylase loss
• no loss of tyrosine hydroxylase immunoreactive nerve terminals
• increased susceptibility to kainic acid damage
• 30-50% neuron loss at kainic acid doses causing only minimal hippocampal damage in controls
• susceptibility to kainic acid damage is not reduced by TNF treatment

behavior/neurological
• reduced food intake at 24 hours but not at 48 hours after caecal ligation and puncture in males
• 44% higher level of generalized convulsions in the 2 hours following 1 hour of electrical stimulation in the hippocampus

respiratory system
• fail to develop fibroproliferative lesions at bronchiolar-alveolar duct junctions when exposed to chrysotile asbestos fibers

cardiovascular system
• more extensive avascular region develops on the retina 17 days after treatment of mice with 75% oxygen for 5 days
• recovery of deep retinal vessels delayed relative to controls
• rate of neovascularization higher at 21 days after treatment than in controls
• 40% larger infarction than controls after coronary artery occlusion
• extent of necrosis in ventricles is similar to controls
• apoptosis peaks earlier and higher than for controls

renal/urinary system
• reduced interstitial volume
• more modest development of progressive interstitial fibrosis after uretera; ligation than in controls
• collagen IV deposition
• improved by enalapril treatment

muscle
• recovery after cardiotoxin damage to the soleus muscle is slowed
• few well defined myofibers 5 days after treatment when the control animal is almost normal
• severe inflammatory infiltration persists through 5 days
• extensive calcium deposits at 5 days
• cross-sectional area of myofibers at 68.7% of pretreatment condition at 12 days after treatment
• contractile force recovery is 53.9% of preatreatment level compared to 75.8% for controls

vision/eye
• more extensive avascular region develops on the retina 17 days after treatment of mice with 75% oxygen for 5 days
• recovery of deep retinal vessels delayed relative to controls
• rate of neovascularization higher at 21 days after treatment than in controls

hematopoietic system
• reduced microglial response to excitotoxic injury

craniofacial
• mice have significantly higher necrosis scores of the dental pulp seven days after bacterial inoculation
• complete necrosis of the dental pulp is observed by 21 days after inoculation compared to control mice that still have intact dental pulp at 38 days post-innoculation

growth/size/body
• mice have significantly higher necrosis scores of the dental pulp seven days after bacterial inoculation
• complete necrosis of the dental pulp is observed by 21 days after inoculation compared to control mice that still have intact dental pulp at 38 days post-innoculation





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory